![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Jupiter Neurosciences is developing JNS101 (resveratrol) is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions.
Lead Product(s): Resveratrol
Therapeutic Area: Genetic Disease Product Name: Jotrol
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Spartan Capital Securities
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 02, 2022